StockData
Vireo Growth Inc. logo

Vireo Growth Inc. (VREOF) stock

VREOFOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/30
$9.01+0.01 (+0.11%)

Close on Oct 19, 2026Market cap $406.23MP/E –Yield –

Vireo Growth operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Vireo Growth's operating income for the twelve months ending Jun 30, 2026 was $1.69M, down 43.7% year over year. For fiscal 2025 it was -$1.05M, down 107.7% from the year before. The highest annual figure on record is $13.56M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.05M-107.7%
FY2024Dec 31, 2024$13.56M+28.2%
FY2023Dec 31, 2023$10.58M–
FY2022Dec 31, 2022-$6.94M–
FY2021Dec 31, 2021-$20.48M–
FY2020Dec 31, 2020-$23.04M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.30M–
Q1 FY2026Mar 31, 2026$9.00M+350.0%
Q4 FY2025Dec 31, 2025-$1.81M–
Q3 FY2025Sep 30, 2025$808.96K-79.0%
Q2 FY2025Jun 30, 2025-$2.00M-134.5%
Q1 FY2025Mar 31, 2025$2.00M-58.0%
Q4 FY2024Dec 31, 2024-$841.55K-115.6%
Q3 FY2024Sep 30, 2024$3.85M-34.4%
Q2 FY2024Jun 30, 2024$5.79M–
Q1 FY2024Mar 31, 2024$4.76M+1191.6%
Q4 FY2023Dec 31, 2023$5.38M+666.9%
Q3 FY2023Sep 30, 2023$5.87M–
Q2 FY2023Jun 30, 2023-$1.04M-438.1%
Q1 FY2023Mar 31, 2023$368.51K–
Q4 FY2022Dec 31, 2022$701.77K–
Q3 FY2022Sep 30, 2022-$189.16K–
Q2 FY2022Jun 30, 2022$308.19K–
Q1 FY2022Mar 31, 2022-$7.76M–
Q4 FY2021Dec 31, 2021-$8.26M–
Q3 FY2021Sep 30, 2021-$4.13M–
Q2 FY2021Jun 30, 2021-$3.25M–
Q1 FY2021Mar 31, 2021-$4.84M–
Q4 FY2020Dec 31, 2020-$2.23M–
Q3 FY2020Sep 30, 2020-$2.27M–
Q2 FY2020Jun 30, 2020-$12.05M–
Q1 FY2020Mar 31, 2020-$6.49M–

More Vireo Growth figures

See a number that looks wrong?